ROXimmune

We are a pre-seed biotech startup developing a first-in-class prodrug platform to treat inflammatory diseases at their root. Our lead program targets Inflammatory Bowel Disease (IBD) and has already demonstrated in vivo proof-of-concept. Unlike conventional therapies that focus on blocking specific pathways or cytokines, our approach tackles the underlying driver of chronic inflammation — oxidative stress. This represents a true paradigm shift in IBD treatment, with a clear path toward expanding into broader autoimmune indications and oncology.